RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

Kodu・Aktsiate loetelu・Lonza Group AG

Lonza Group AG

Suletud

SektorTervishoid

493.4 3.09

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

478.65

Max

494.2

Põhinäitajad
By Trading Economics
Sissetulek	57M 483M
Müük	-621M 3B
P/E Sektori keskmine	37.585 67.147
Dividenditootlus	1.04
Kasumimarginaal	16.345
Töötajad	20,000
EBITDA	-181M 822M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+37.73% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	1.04% 2.36%
Järgmine tulemuste avaldamine	22. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-4.6B 34B
Eelmine avamishind	490.31
Eelmine sulgemishind	493.4

Uudiste sentiment

By Acuity

14%

86%

24 / 347 Pingereas Healthcare

Lonza Group AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. märts 2026, 17:44 UTC

Omandamised, ülevõtmised, äriostud

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

28. jaan 2026, 06:15 UTC

Tulu

Lonza Sales Grow on New Contract Momentum

23. juuli 2025, 08:30 UTC

Tulu

Suurimad hinnamuutused turgudel

Lonza Shares Rise After Outlook Lift for Core Business

9. märts 2026, 10:34 UTC

Market Talk

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

6. märts 2026, 17:12 UTC

Omandamised, ülevõtmised, äriostud

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

6. märts 2026, 17:10 UTC

Omandamised, ülevõtmised, äriostud

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

6. märts 2026, 17:09 UTC

Omandamised, ülevõtmised, äriostud

Lonza to Retain 40% Stake in CHI

6. märts 2026, 17:08 UTC

Omandamised, ülevõtmised, äriostud

Lonza Will Receive Upfront Proceeds of CHF1.7B

6. märts 2026, 17:07 UTC

Omandamised, ülevõtmised, äriostud

Lonza: Transaction Expected to Close in 2H

6. märts 2026, 17:07 UTC

Omandamised, ülevõtmised, äriostud

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

6. märts 2026, 17:06 UTC

Omandamised, ülevõtmised, äriostud

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

28. jaan 2026, 12:04 UTC

Market Talk

Tulu

Lonza Results Show a Company in Good Shape -- Market Talk

28. jaan 2026, 05:35 UTC

Tulu

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

28. jaan 2026, 05:34 UTC

Tulu

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

28. jaan 2026, 05:33 UTC

Tulu

Lonza Issues 2026 View

28. jaan 2026, 05:32 UTC

Tulu

Lonza 2025 Core Ebitda Margin 31.6%

28. jaan 2026, 05:32 UTC

Tulu

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

28. jaan 2026, 05:32 UTC

Tulu

Lonza 2025 Core Ebitda CHF2.06B

28. jaan 2026, 05:30 UTC

Tulu

Analysts Saw Lonza 2025 Sales at CHF7.54B

28. jaan 2026, 05:30 UTC

Tulu

Lonza 2025 Sales CHF6.53B

27. okt 2025, 08:24 UTC

Market Talk

Lonza on Track to Meet Long-Term Goals -- Market Talk

23. okt 2025, 10:53 UTC

Market Talk

Tulu

Lonza Set to Recover as Contracts Flow in -- Market Talk

23. juuli 2025, 08:00 UTC

Market Talk

Tulu

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

23. juuli 2025, 04:44 UTC

Tulu

Lonza 1H Sales Grew 19% at Constant Currency

23. juuli 2025, 04:43 UTC

Tulu

Lonza 1H Core Ebitda Margin 29.6%

23. juuli 2025, 04:43 UTC

Tulu

Lonza: Margins Will Be Only Minimally Affected

23. juuli 2025, 04:42 UTC

Tulu

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

23. juuli 2025, 04:42 UTC

Tulu

Lonza: This Is Mainly From Weakening of U.S. Dollar

23. juuli 2025, 04:38 UTC

Tulu

Lonza 1H Net Pft CHF426M

23. juuli 2025, 04:37 UTC

Tulu

Lonza Backs 2025 View for CHI Business

Võrdlus sarnastega

Hinnamuutus

Lonza Group AG Prognoos

Hinnasiht

By TipRanks

37.73% tõus

12 kuu keskmine prognoos

Keskmine 660 CHF 37.73%

Kõrge 670 CHF

Madal 630 CHF

Põhineb 4 Wall Streeti analüütiku instrumendi Lonza Group AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lonza Group AG aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

24 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.